EyePoint Pharmaceuticals ... (EYPT)
NASDAQ: EYPT
· Real-Time Price · USD
10.59
-0.26 (-2.40%)
At close: Aug 15, 2025, 10:20 AM
-2.40% (1D)
| Bid | 10.54 |
| Market Cap | 729.6M |
| Revenue (ttm) | 51.9M |
| Net Income (ttm) | -175.38M |
| EPS (ttm) | -2.69 |
| PE Ratio (ttm) | -3.93 |
| Forward PE | -3.64 |
| Analyst | Buy |
| Ask | 13.67 |
| Volume | 179,726 |
| Avg. Volume (20D) | 798,167 |
| Open | 10.89 |
| Previous Close | 10.85 |
| Day's Range | 10.57 - 10.93 |
| 52-Week Range | 3.91 - 13.99 |
| Beta | 1.75 |
About EYPT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EYPT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EYPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
EyePoint Pharmaceuticals has released their quartely earnings
on Aug 6, 2025:
Next Earnings Release
EyePoint Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+18.12%
EyePoint shares are trading higher after the compa...
Unlock content with
Pro Subscription
6 months ago
+2.36%
EyePoint Pharmaceuticals shares are trading higher after the company announced six-month results for its Phase 2 VERONA trial and stated the trial met its primary endpoint.
1 week ago · fool.com
EyePoint (EYPT) Q2 Revenue Drops 44%EyePoint (EYPT) Q2 Revenue Drops 44%
2 months ago · seekingalpha.com
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent...
